NTRA – natera, inc. (US:NASDAQ)
Stock Stats
News
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $260.00. They now have an "overweight" rating on the stock.
Natera (NASDAQ:NTRA) was given a new $205.00 price target on by analysts at Wells Fargo & Company.
Natera (NASDAQ:NTRA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
Form 4 Natera, Inc. For: Oct 31 Filed by: ROSENMAN HERM
Form 4 Natera, Inc. For: Dec 12 Filed by: Moshkevich Solomon
Form 144 Natera, Inc. Filed by: Moshkevich Solomon
Form 144 Natera, Inc. Filed by: ROSENMAN HERM
Form 4 Natera, Inc. For: Dec 09 Filed by: Sheena Jonathan
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.